The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. / Antonova, Maria; Wienecke, Troels; Maubach, Karen; Thomas, Emma; Olesen, Jes; Ashina, Messoud.

I: Journal of Headache and Pain, Bind 12, Nr. 5, 2011, s. 551-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Antonova, M, Wienecke, T, Maubach, K, Thomas, E, Olesen, J & Ashina, M 2011, 'The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache', Journal of Headache and Pain, bind 12, nr. 5, s. 551-9. https://doi.org/10.1007/s10194-011-0358-9

APA

Antonova, M., Wienecke, T., Maubach, K., Thomas, E., Olesen, J., & Ashina, M. (2011). The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. Journal of Headache and Pain, 12(5), 551-9. https://doi.org/10.1007/s10194-011-0358-9

Vancouver

Antonova M, Wienecke T, Maubach K, Thomas E, Olesen J, Ashina M. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. Journal of Headache and Pain. 2011;12(5):551-9. https://doi.org/10.1007/s10194-011-0358-9

Author

Antonova, Maria ; Wienecke, Troels ; Maubach, Karen ; Thomas, Emma ; Olesen, Jes ; Ashina, Messoud. / The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. I: Journal of Headache and Pain. 2011 ; Bind 12, Nr. 5. s. 551-9.

Bibtex

@article{1e194dfba62a4c3c89244b383870dcea,
title = "The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache",
abstract = "Using a human Prostaglandin E(2) (PGE(2)) model of headache, we examined whether a novel potent and selective EP(4) receptor antagonist, BGC20-1531, may prevent headache and dilatation of the middle cerebral (MCA) and superficial temporal artery (STA). In a three-way cross-over trial, eight healthy volunteers were randomly allocated to receive 200 and 400 mg BGC20-1531 and placebo, followed by a 25-min infusion of PGE(2). We recorded headache intensity on a verbal rating scale, MCA blood flow velocity and STA diameter. There was no difference in headache response or prevention of the dilation of the MCA or the STA (P > 0.05) with either dose of BGC20-1531 relative to placebo, although putative therapeutic exposures were not reached in all volunteers. In conclusion, these data suggest that the other EP receptors may be involved in PGE(2) induced headache and dilatation in normal subjects.",
author = "Maria Antonova and Troels Wienecke and Karen Maubach and Emma Thomas and Jes Olesen and Messoud Ashina",
year = "2011",
doi = "http://dx.doi.org/10.1007/s10194-011-0358-9",
language = "English",
volume = "12",
pages = "551--9",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache

AU - Antonova, Maria

AU - Wienecke, Troels

AU - Maubach, Karen

AU - Thomas, Emma

AU - Olesen, Jes

AU - Ashina, Messoud

PY - 2011

Y1 - 2011

N2 - Using a human Prostaglandin E(2) (PGE(2)) model of headache, we examined whether a novel potent and selective EP(4) receptor antagonist, BGC20-1531, may prevent headache and dilatation of the middle cerebral (MCA) and superficial temporal artery (STA). In a three-way cross-over trial, eight healthy volunteers were randomly allocated to receive 200 and 400 mg BGC20-1531 and placebo, followed by a 25-min infusion of PGE(2). We recorded headache intensity on a verbal rating scale, MCA blood flow velocity and STA diameter. There was no difference in headache response or prevention of the dilation of the MCA or the STA (P > 0.05) with either dose of BGC20-1531 relative to placebo, although putative therapeutic exposures were not reached in all volunteers. In conclusion, these data suggest that the other EP receptors may be involved in PGE(2) induced headache and dilatation in normal subjects.

AB - Using a human Prostaglandin E(2) (PGE(2)) model of headache, we examined whether a novel potent and selective EP(4) receptor antagonist, BGC20-1531, may prevent headache and dilatation of the middle cerebral (MCA) and superficial temporal artery (STA). In a three-way cross-over trial, eight healthy volunteers were randomly allocated to receive 200 and 400 mg BGC20-1531 and placebo, followed by a 25-min infusion of PGE(2). We recorded headache intensity on a verbal rating scale, MCA blood flow velocity and STA diameter. There was no difference in headache response or prevention of the dilation of the MCA or the STA (P > 0.05) with either dose of BGC20-1531 relative to placebo, although putative therapeutic exposures were not reached in all volunteers. In conclusion, these data suggest that the other EP receptors may be involved in PGE(2) induced headache and dilatation in normal subjects.

U2 - http://dx.doi.org/10.1007/s10194-011-0358-9

DO - http://dx.doi.org/10.1007/s10194-011-0358-9

M3 - Journal article

VL - 12

SP - 551

EP - 559

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 5

ER -

ID: 40140763